RICHLAND, WASHINGTON – August 13, 2019 – Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc.’s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for...
New Brand Identity to Be Unveiled Thursday, June 13 RICHLAND, WASHINGTON – June 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced...
Record Revenue and Gross Profit Revenue Increased 22% Year-Over-Year RICHLAND, WASHINGTON – May 9, 2019 — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
Conference Call is May 9 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – May 1, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it...
Photo curtesy of The Boston Herald. Boston Herald Reporter Alexi Cohan recently joined Dr. Peter Orio on the “front lines” in order to learn more about brachytherapy for prostate cancer treatment. This article details the brachytherapy procedure process and the...
RICHLAND, WASHINGTON – April 16, 2019 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced a new training collaboration with Texas Oncology. The...
After nearly 10 years and more than 12,000 patients treated following its FDA approval for prostate cancer treatment, sufficient scientific data and patient-reported evidence suggest that Cesium-131 delivers equivalent to, or superior outcomes compared to Iodine and...
Transition concerns should not stop you from adding Cesium to your prostate brachytherapy practice. With a thoughtful approach to planning and the right support, you can seamlessly upgrade your prostate brachytherapy to the power of Cesium. Dr. Bernard Taylor has...
Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year RICHLAND, WASHINGTON – February 12, 2019 — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...
WCIV-TV reports on the world’s first use of the Blu Build Cesium-131 brachytherapy delivery system at Hollings Cancer Center. Here’s the story on this important medical advance for prostate cancer patients and the doctors who treat...
